Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.

作者: Saskia M M Jacobs , Denis H A van Beurden , Leo W J Klomp , Ruud Berger , Inge E T van den Berg

DOI: 10.1203/01.PDR.0000198810.57642.B4

关键词:

摘要: Children with hereditary tyrosinemia type 1 (HT1) suffer from liver failure, renal tubular dysfunction, and rickets. The disease is caused by deficiency of fumarylacetoacetate hydrolase (FAH), the last enzyme tyrosine catabolism, leads to accumulation toxic substrate (FAA) in hepatocytes proximal cells. Patients are treated 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3 cyclohexanedione (NTBC), which prevents FAA blocking an upstream FAH. Liver transplantation performed when patients do not respond NTBC or develop hepatocellular carcinoma. This reduces load for kidney but does abolish exposure locally produced FAA. To investigate pathogenesis damage induced metabolites, we challenged FAH-deficient mice various doses homogentisic acid (HGA), a precursor Injecting NTBC-treated Fah−/−mice low HGA death cells, as was shown histologic analyses deoxynucleotidyl transferase-mediated dUDP nick-end labeling (TUNEL) assay did lead damage. In addition, function, affected after HGA. Administration high led massive cell both kidneys. Resistance HGA-induced seen withdrawing Fah−/−mice. finding that kidneys especially sensitive underscores need perform careful monitoring function undergoing any form treatment.

参考文章(27)
Kvittingen Ea, Hereditary tyrosinemia type I--an overview. Scandinavian Journal of Clinical & Laboratory Investigation. ,vol. 184, pp. 27- 34 ,(1986)
S. Z. Kim, K. G. Kupke, L. Ierardi-Curto, E. Holme, J. Greter, R. M. Tanguay, J. Poudrier, M. D'Astous, F. Lettre, S. H. Hahn, H. L. Levy, Hepatocellular carcinoma despite long-term survival in chronic tyrosinaemia I Journal of Inherited Metabolic Disease. ,vol. 23, pp. 791- 804 ,(2000) , 10.1023/A:1026756501669
E. Holme, S. Lindstedt, Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). Journal of Inherited Metabolic Disease. ,vol. 21, pp. 507- 517 ,(1998) , 10.1023/A:1005410820201
Ryckman Fc, Balistreri Wf, Shoemaker Lr, Strife Cf, Rapid improvement in the renal tubular dysfunction associated with tyrosinemia following hepatic replacement. Pediatrics. ,vol. 89, pp. 251- 255 ,(1992)
R M Tanguay, C Laberge, M Plante, J L Duband, A Lescault, F Lettre, J P Valet, Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). American Journal of Human Genetics. ,vol. 47, pp. 308- 316 ,(1990)
Pierre A. Russo, Grant A. Mitchell, Robert M. Tanguay, Tyrosinemia: A Review Pediatric and Developmental Pathology. ,vol. 4, pp. 212- 221 ,(2001) , 10.1007/S100240010146
Sylviane Forget, H. B. Patriquin, Josée Dubois, Maud Lafortune, Aicha Merouani, Khazal Paradis, Pierre Russo, The kidney in children with tyrosinemia: sonographic, CT and biochemical findings. Pediatric Radiology. ,vol. 29, pp. 104- 108 ,(1999) , 10.1007/S002470050551
Francjan J. van Spronsen, Charles M. A. Bijleveld, Bianca T. van Maldegem, Frits A. Wijburg, Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment Journal of Pediatric Gastroenterology and Nutrition. ,vol. 40, pp. 90- 93 ,(2005) , 10.1097/00005176-200501000-00017
Rossana Jorquera, Robert M. Tanguay, The Mutagenicity of the Tyrosine Metabolite, Fumarylacetoacetate, Is Enhanced by Glutathione Depletion Biochemical and Biophysical Research Communications. ,vol. 232, pp. 42- 48 ,(1997) , 10.1006/BBRC.1997.6220